1	Title: A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on
2	Repeat Infection.
3	
4	Authors:
5	Kojima N ¹ ; Shrestha NK ² ; and Klausner JD ³
6	
7	¹ Department of Medicine, University of California Los Angeles, Los Angeles, 90095
8	² Department of Infectious Diseases, Cleveland Clinic, Cleveland, 44195
9	³ Departments of Medicine and Population and Public Health Sciences, Keck School of
10	Medicine, University Southern California, Los Angeles, 90032
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	Corresponding Author Contact Information:
22	Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA
23	90095. Email: nkojima@ucla.edu

24 25 **Abstract** 26 Introduction: We systematically reviewed studies to estimate the risk of SARS-CoV-2 27 reinfection among those previously infected with SARS-CoV-2. 28 Methods: For this systematic review, we searched scientific publications on PubMed 29 and, the pre-print server, MedRxiv through August 18, 2021. Eligible studies were 30 retrieved on August 18, 2021. We used the following search term on PubMed: 31 ((("Cohort Studies"[Mair]) AND ("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh])) OR 32 "Reinfection"[Majr]) OR "Reinfection"[Mesh]. We used the following search term on 33 MedRxiv: "Cohort Studies" AND "COVID-19" OR "SARS-CoV-2" AND "Reinfection". 34 The search terms were broad to encompass all possibilities for applicable studies. 35 There were no restrictions on the date of publication. Studies that did not describe 36 cohorts with estimates of the risk of SARS-CoV-2 reinfection among those with previous 37 infection were excluded. Studies that included vaccinated participants were either 38 excluded or limited to sub-groups of non-vaccinated individuals. To identify relevant 39 studies with appropriate control groups, we developed the following criteria for studies 40 to be included in the systematic analysis: (1) baseline polymerase chain reaction (PCR) 41 testing, (2) a negative comparison group, (3) longitudinal follow-up, (4) a cohort of 42 human participants, i.e., not a case report or case series, and (5) outcome determined 43 by PCR. The review was conducted following PRISMA guidelines. We assessed for 44 selection, information, and analysis bias, per PRISMA guidelines. 45 **Results:** We identified 1,392 reports. Of those, 10 studies were eligible for our 46 systematic review. The weighted average risk reduction against reinfection was 90.4%

- 47 with a standard deviation of 7.7%. Protection against SARS-CoV-2 reinfection was
- observed for up to 10 months. Studies had potential information, selection, and analysis
- 49 biases.
- 50 **Conclusions:** The protective effect of prior SARS-CoV-2 infection on re-infection is
- 51 high and similar to the protective effect of vaccination. More research is needed to
- 52 characterize the duration of protection and the impact of different SARS-CoV-2 variants.

MAIN TEXT

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is highly infectious and continues to cause substantial morbidity and mortality (Dong et al., 2020; Jin et al., 2020). Prior to the development of highly safe and effective vaccines for SARS-CoV-2 infection, scientists reported that a history of COVID-19 was associated with reduced risk of SARS-CoV-2 reinfection (Addetia et al., 2020). Virus-induced immunity has been described in many infections and is responsible for the decline of epidemic spread associated with exhaustion of the susceptible population (Rouse & Sehrawat, 2010). However, the duration and degree of the protective effect of SARS-CoV-2s-induced immunity is poorly studied. Prior epidemiologic studies have found that individuals who are SARS-CoV-2 antibodypositive are protected against reinfection (Abu-Raddad et al., 2021; Harvey et al., 2021; Jeffery-Smith et al., 2021). Furthermore, investigators have reported that even those with prior SARS-CoV-2 infection who lacked detectable antibodies were at 80% lower risk of reinfection than people who were SARS-CoV-2 naïve (Breathnach et al., 2021). One retrospective study that analyzed test results among nearly 10,000 individuals with prior SARS-CoV-2 infection found that only 0.7% became reinfected with SARS-CoV-2 (Qureshi et al., 2021).

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

Other studies have also described reduced risk of infection, morbidity, and mortality among those with prior COVID-19. A study conducted in Austria found that the frequency of hospitalization and death due to a SARS-CoV-2 reinfection was 5 out of 14,840 (0.03%) and 1 out of 14,840 (0.01%), respectively (Pilz et al., 2021). A history of COVID-19 may be as protective against reinfection as vaccination for SARS-CoV-2. A study investigating the frequency of repeat infection among laboratory personnel undergoing daily testing found no difference in SARS-CoV-2 infection rates between those with prior COVID-19 versus those vaccinated for SARS-CoV-2 infection (Kojima et al., 2021). Thompson et al. also reported that the decrease in risk of SARS-CoV-2 reinfection among those with prior infection was similar in magnitude to the relative risk reduction against SARS-CoV-2 infection among those who were vaccinated (Thompson et al., 2021). In a longitudinal study conducted among employees at the Cleveland Clinic, vaccination was not found to be associated with a lower risk of SARS-CoV-2 infection among people with prior COVID-19 (Shrestha et al., 2021). Despite the availability of safe and effective vaccines, rates of SARS-CoV-2 infection are again increasing, especially among those without immunity (Christie et al., 2021). We aimed to determine the protective effect of previous infection among those who have not been also vaccinated against SARS-CoV-2. We systematically reviewed published longitudinal studies to estimate the risk of SARS-CoV-2 reinfection among those previously infected with SARS-CoV-2.

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Methods For this systematic review, we searched scientific publications on PubMed and the preprint server, MedRxiv. through August 18, 2021. Eligible studies were retrieved on August 18, 2021. We used the following search term on PubMed: ((("Cohort Studies"[Majr]) AND ("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh])) OR "Reinfection"[Majr]) OR "Reinfection"[Mesh]. We used the following search term on MedRxiv: "Cohort Studies" AND "COVID-19" OR "SARS-CoV-2" AND "Reinfection". The search terms were broad to encompass all possibilities for applicable studies. There were no restrictions on the date of publication. Studies that did not describe cohorts with estimates of the risk of SARS-CoV-2 reinfection among those with previous infection were excluded. Studies that included vaccinated participants were either excluded or limited to sub-groups of non-vaccinated individuals. To identify relevant studies with appropriate control groups, we developed the following criteria for studies to be included in the systematic analysis: (1) baseline polymerase chain reaction (PCR) testing, (2) a negative comparison group, (3) longitudinal follow-up, (4) a cohort of human participants, i.e., not a case report or case series, and (5) outcome determined by PCR. The review was conducted following PRISMA guidelines (Page et al., 2021). Two reviewers identified studies for the review. One reviewer collected data from each report and the other reviewer independently checked the work. Abstracts were reviewed and

Final Version 6

ineligible studies were not included. We reviewed selected reports to extract the

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

following information: Author, year of publication, study cohort, reinfection risk, and follow-up time in person-years, when available. We assessed for selection, information, and analysis bias, per PRISMA guidelines. Due to the heterogeneity of the studies reviewed, sensitivity analyses and a meta-analysis was not attempted. Studies with outcomes were listed in a table. There was no funding for this study. **Results** We identified 1,392 reports (Figure). Of those reports, 10 studies met the above criteria from 6 different countries. The total population in the 10 studies included 9,930,470 individuals with a median observation period that ranged from one to 10.3 months. We found that the relative decreased risk of SARS-CoV-2 reinfection ranged between 80.5 to 100% compared to those without prior infection (Table). The weighted average risk reduction against reinfection was 90.4%, with a standard deviation of 7.7%. The studies conducted by Goldberg et al., Hansen et al., Pilz et al., and Vitale et al., had cohorts compiled from national databases, which may have generated a selection bias towards people who had access to SARS-CoV-2 testing and were registered (Goldberg et al., 2021; Hansen et al., 2021; Pilz et al., 2021; Vitale et al., 2021). The study conducted by Hall et al. followed a cohort of 30,625 participants (Hall et al., 2021). In their study 51 participants withdrew and 4,913 participants were excluded because they

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

did not have linked data for SARS-CoV-2 testing. That may have biased their study against people who did not have follow up testing, i.e., information and analysis bias. The study conducted by Letizia et al. studied young and healthy adults in the United States Marines who were undergoing basic training, and the housing conditions and interactions of individuals in that setting would not be readily extrapolated to the average population (Letizia et al., 2021). The study conducted by Rennert et al. studied university students that are younger and healthier than the average population (Rennert & McMahan, 2021). The study conducted by Shrestha et al. included younger and relatively healthier people, and since the study was done entirely after vaccines became available, there was also likely selection bias due to differential participation among those who decided not to get vaccinated (Shrestha et al., 2021). The studies conducted by Hall et al., Rennert et al., and Sheehan et al., included followup that extended into the period when vaccines became available, and since vaccination was not controlled for, it is likely that vaccination among some subjects in the previously uninfected groups would have resulted in information bias resulting in an underestimation or overestimation of the effect size (Hall et al., 2021; Rennert & McMahan, 2021; Sheehan et al., 2021). **Discussion** We systematically reviewed published longitudinal studies of SARS-CoV-2 reinfection

Final Version 8

with PCR confirmed initial and repeat infections. We found that the weighted average

risk reduction against reinfection was 90.4%. Protection was observed up to 10 months.

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

People with prior COVID-19 had a similar and durable level of protection when compared to those vaccinated against SARS-CoV-2 (Kojima et al., 2021; Stephens & McElrath, 2020). In our systematic review, protection against SARS-CoV-2 reinfection was observed in up to 10 months following initial infection. It is not clear how long natural protection after infection will last. Biological studies have found persistent reservoirs of immunological active and antibody producing cells for up to 10 months or longer (Cohen et al., 2021). The studies were conducted in 6 different countries. The studies ranged from participants that were younger than the national average (Letizia et al., 2021; Rennert & McMahan, 2021), as well as populations that were older than the national average (Vitale et al., 2021). Some studies followed participants at a national level (Goldberg et al., 2021; Hansen et al., 2021; Pilz et al., 2021), whereas other studies more closely followed cohorts (Letizia et al., 2021; Rennert & McMahan, 2021). While methodologies of studies differed, all reviewed studies consistently found decreased risk of reinfection among people with prior SARS-CoV-2 infection. A recent United States Centers of Disease Control and Prevention (CDC) investigation conducted in Kentucky among persons with prior COVID-19 found that vaccination enhanced the protection of those with prior infection (Cavanaugh et al., 2021). In the CDC study, lack of vaccination after infection was associated with an increased odds of repeat SARS-CoV-2 infection, although the absolute increased risk of re-infection was

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

very low. The study may have been biased due to different risk behaviors of the cases and controls. The study was not controlled for adherence with pandemic precautions (masking and social distancing), which would have been expected to have been different in the cases and controls. Our study had several limitations. Our review was limited to studies with PCR confirmation of infection and re-infection. Multiple other studies, however, using SARS-CoV-2 antibody status as a measure of infection have similar results (Abu-Raddad et al., 2021; Harvey et al., 2021; A Leidi et al., 2021; A. Leidi et al., 2021). Our systematic review utilized some studies published on MedRxiv, a pre-print server. While MedRxiv had been helpful during the COVID-19 pandemic due to the rapid ability to disseminate information to colleagues, studies that were accessed on the site were not peerreviewed. Furthermore, many of the studies cannot be replicated because they occurred in settings prior to the availability of vaccination against SARS-CoV-2 among people with history of infection. Many of the studies including in our review followed people infected with SARS-CoV-2 earlier in the pandemic when infection was most likely with the original wildtype strain of SARS-CoV-2 before the development of variant strains. Therefore, our findings may differ in the current context of infections with exposure to variants that differ from the original infecting variant.

However a recent pre-print from a study conducted in the United Kingdom found among persons infected during a period of nearly exclusive Delta SARS-CoV-2 transmission, those fully vaccinated with BNT162b2 and ChAd0x1 (had similar levels of protection (82% and 67%, respectively) as those with previous infection (73%) (Pouwels; et al., 2021). Additionally, in a recent retrospective cohort study that was conducted in Israel which compared rates of SARS-CoV-2 infection or reinfection with the Delta variant among SARS-CoV-2-naïve individuals who received the BNT162b2 vaccine to people who had recovered from COVID-19, found that vaccinated, but SARS-CoV-2-naïve people, had an increased risk of infection with the Delta variant when compared to people who had recovered from COVID-19 (Gazit et al., 2021). This association was statistically significant in two models that either matched to the time of the first event (13.1-fold increased risk) or did not match to time of first event (6.0-fold increased risk).

Implications

Our findings suggest that persons with prior COVID-19 are protected against SARS-CoV-2 reinfection. While protection has been observed in up to 10 months after initial infection, it is unclear how long the protection will last. Given the recency of new circulating variants like Delta, the protective effect of a previous infection with one variant and exposure to a different variant are uncertain. However, recent studies during the period of transmission of the Delta variant are promising.

Conclusions

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

There is consistent epidemiologic evidence that prior SARS-CoV-2 infection provides substantial immunity to repeat SARS-CoV-2 infection. Prior SARS-CoV-2 infections provide similar protection when compared to vaccination for SARS-CoV-2. Longer follow-up studies are needed to determine how long protection lasts for natural immunity, especially among higher risk groups such as those with chronic medical conditions and those that are immunocompromised. More research is needed to investigate whether disease severity changes the risk of repeat infection. Finally, more research is needed to determine how much protection persists against emerging variants, like the Delta variant of SARS-CoV-2. **Declarations** Declaration of competing interests NK has received consulting fees from Curative Inc. JDK serves as Medical Director of Curative Inc. **Funding** None Acknowledgements None

254 References 255 Abu-Raddad, L. J., Chemaitelly, H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, 256 Y. A., Younuskunju, S., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Butt, A. A., 257 Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., 258 Nasrallah, G. K., Yassine, H. M., Al Kuwari, M. G., Al Romaihi, H. E., Al-Thani, 259 M. H., Al Khal, A., & Bertollini, R. (2021). SARS-CoV-2 antibody-positivity 260 protects against reinfection for at least seven months with 95% efficacy. 261 EClinicalMedicine, 35, 100861. https://doi.org/10.1016/j.eclinm.2021.100861 262 Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M. L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020). Neutralizing Antibodies 263 264 Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel 265 Outbreak with a High Attack Rate. J Clin Microbiol, 58(11). 266 https://doi.org/10.1128/JCM.02107-20 267 Breathnach, A. S., Duncan, C. J. A., Bouzidi, K. E., Hanrath, A. T., Payne, B. A. I., 268 Randell, P. A., Habibi, M. S., Riley, P. A., Planche, T. D., Busby, J. S., 269 Sudhanva, M., Pallett, S. J. C., & Kelleher, W. P. (2021). Prior COVID-19 270 protects against reinfection, even in the absence of detectable antibodies. J 271 Infect, 83(2), 237-279. https://doi.org/10.1016/j.jinf.2021.05.024 272 Cavanaugh, A., Spicer, K., Thoroughman, D., Glick, C., & Winter, K. (2021). Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, 273 274 May-June 2021. MMWR Morb Mortal Wkly Rep. https://doi.org/10.15585/mmwr.mm7032e1 275

276 Christie, A., Brooks, J. T., Hicks, L. A., Sauber-Schatz, E. K., Yoder, J. S., Honein, M. 277 A., & Team, C. C.-R. (2021). Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and 278 279 Vaccination Coverage. MMWR Morb Mortal Wkly Rep., 70(30), 1044-1047. 280 https://doi.org/10.15585/mmwr.mm7030e2 281 Cohen, K. W., Linderman, S. L., Moodie, Z., Czartoski, J., Lai, L., Mantus, G., Norwood, 282 C., Nyhoff, L. E., Edara, V. V., Floyd, K., De Rosa, S. C., Ahmed, H., Whaley, R., 283 Patel, S. N., Prigmore, B., Lemos, M. P., Davis, C. W., Furth, S., O'Keefe, J. B., 284 Gharpure, M. P., Gunisetty, S., Stephens, K., Antia, R., Zarnitsyna, V. I., 285 Stephens, D. S., Edupuganti, S., Rouphael, N., Anderson, E. J., Mehta, A. K., 286 Wrammert, J., Suthar, M. S., Ahmed, R., & McElrath, M. J. (2021). Longitudinal 287 analysis shows durable and broad immune memory after SARS-CoV-2 infection 288 with persisting antibody responses and memory B and T cells. Cell Rep Med, 289 2(7), 100354. https://doi.org/10.1016/j.xcrm.2021.100354 290 Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track 291 COVID-19 in real time. Lancet Infect Dis, 20(5), 533-534. 292 https://doi.org/10.1016/S1473-3099(20)30120-1 293 Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Cohen, D., 294 Muhsen, K., Chodick, G., & Patalon, T. (2021). Comparing SARS-CoV-2 natural 295 immunity to vaccine-induced immunity: reinfections versus breakthrough 296 infections. *medRxiv*. https://doi.org/10.1101/2021.08.24.21262415 297 Goldberg, Y., Mandel, M., Woodbridge, Y., Fluss, R., Novikov, I., Yaari, R., Ziv, A., 298 Freedman, L., & Huppert, A. (2021). Protection of previous SARS-CoV-2

299 infection is similar to that of BNT162b2 vaccine protection: A three-month 300 nationwide experience from Israel. *medRxiv*. 301 Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., Wellington, 302 E., Cole, M. J., Saei, A., Oguti, B., Munro, K., Wallace, S., Kirwan, P. D., Shrotri, 303 M., Vusirikala, A., Rokadiya, S., Kall, M., Zambon, M., Ramsay, M., Brooks, T., 304 Brown, C. S., Chand, M. A., Hopkins, S., & Group, S. S. (2021). SARS-CoV-2 305 infection rates of antibody-positive compared with antibody-negative health-care 306 workers in England: a large, multicentre, prospective cohort study (SIREN). 307 Lancet, 397(10283), 1459-1469. https://doi.org/10.1016/S0140-6736(21)00675-9 308 Hansen, C. H., Michlmayr, D., Gubbels, S. M., Molbak, K., & Ethelberg, S. (2021). 309 Assessment of protection against reinfection with SARS-CoV-2 among 4 million 310 PCR-tested individuals in Denmark in 2020: a population-level observational 311 study. Lancet, 397(10280), 1204-1212. https://doi.org/10.1016/S0140-312 6736(21)00575-4 313 Harvey, R. A., Rassen, J. A., Kabelac, C. A., Turenne, W., Leonard, S., Klesh, R., 314 Meyer, W. A., 3rd, Kaufman, H. W., Anderson, S., Cohen, O., Petkov, V. I., 315 Cronin, K. A., Van Dyke, A. L., Lowy, D. R., Sharpless, N. E., & Penberthy, L. T. 316 (2021). Association of SARS-CoV-2 Seropositive Antibody Test With Risk of 317 Future Infection. JAMA Intern Med, 181(5), 672-679. 318 https://doi.org/10.1001/jamainternmed.2021.0366 319 Jeffery-Smith, A., Iyanger, N., Williams, S. V., Chow, J. Y., Aiano, F., Hoschler, K., 320 Lackenby, A., Ellis, J., Platt, S., Miah, S., Brown, K., Amirthalingam, G., Patel, 321 M., Ramsay, M. E., Gopal, R., Charlett, A., Ladhani, S. N., & Zambon, M. (2021).

322 Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care 323 homes, September and October 2020. Euro Surveill, 26(5). 324 https://doi.org/10.2807/1560-7917.ES.2021.26.5.2100092 325 Jin, H., Liu, J., Cui, M., & Lu, L. (2020). Novel coronavirus pneumonia emergency in 326 Zhuhai: impact and challenges. J Hosp Infect, 104(4), 452-453. 327 https://doi.org/10.1016/j.jhin.2020.02.005 328 Kojima, N., Roshani, A., Brobeck, M., Baca, A., & Klausner, J. D. (2021). Incidence of 329 Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously 330 infected or vaccinated employees. *medRxiv*. 331 https://doi.org/10.1101/2021.07.03.21259976 332 Leidi, A., Berner, A., Roxane, D., Dubos, R., Koegler, F., Piumatti, G., Vuilleumier, N., 333 Kaiser, L., Balavoine, J. F., Trono, D., Pittet, D., Chappuis, F., Kherad, O., 334 Courvoisier, D., Azman, A. S., Zaballa, M. E., Guessous, I., & Stringhini, S. 335 (2021). Occupational risk of SARS-CoV-2 infection and reinfection during the 336 second pandemic surge: a cohort study. *medRxiv*. 337 https://doi.org/10.1101/2021.08.06.21261419 338 Leidi, A., Koegler, F., Dumont, R., Dubos, R., Zaballa, M. E., Piumatti, G., Coen, M., Berner, A., Darbellay Farhoumand, P., Vetter, P., Vuilleumier, N., Kaiser, L., 339 340 Courvoisier, D., Azman, A. S., Guessous, I., Stringhini, S., & group, S. E.-P. s. 341 (2021). Risk of reinfection after seroconversion to SARS-CoV-2: A population-342 based propensity-score matched cohort study. Clin Infect Dis. 343 https://doi.org/10.1093/cid/ciab495

344 Letizia, A. G., Ge, Y., Vangeti, S., Goforth, C., Weir, D. L., Kuzmina, N. A., Balinsky, C. 345 A., Chen, H. W., Ewing, D., Soares-Schanoski, A., George, M. C., Graham, W. D., Jones, F., Bharai, P., Lizewski, R. A., Lizewski, S. E., Marayag, J., 346 347 Marjanovic, N., Miller, C. M., Mofsowitz, S., Nair, V. D., Nunez, E., Parent, D. M., 348 Porter, C. K., Santa Ana, E., Schilling, M., Stadlbauer, D., Sugiharto, V. A., 349 Termini, M., Sun, P., Tracy, R. P., Krammer, F., Bukreyev, A., Ramos, I., & 350 Sealfon, S. C. (2021). SARS-CoV-2 seropositivity and subsequent infection risk 351 in healthy young adults: a prospective cohort study. Lancet Respir Med. 352 https://doi.org/10.1016/S2213-2600(21)00158-2 353 Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. 354 D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, 355 J., Grimshaw, J. M., Hrobjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-356 Wilson, E., McDonald, S., McGuinness, L. A., Stewart, L. A., Thomas, J., Tricco, 357 A. C., Welch, V. A., Whiting, P., & Moher, D. (2021). The PRISMA 2020 358 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. 359 https://doi.org/10.1136/bmj.n71 360 Pilz, S., Chakeri, A., Ioannidis, J. P., Richter, L., Theiler-Schwetz, V., Trummer, C., 361 Krause, R., & Allerberger, F. (2021). SARS-CoV-2 re-infection risk in Austria. Eur 362 J Clin Invest, 51(4), e13520. https://doi.org/10.1111/eci.13520 363 Pouwels;, K. B., Pritchard;, E., Matthews;, P. C., Stoesser;, N., Eyre;, D. W., Vihta;, K.-364 D., House;, T., Hay;, J., Bell;, J. I., Newton;, J. N., Farrar;, J., Crook;, D., Cook;, D., Rourke;, E., Studley;, R., Peto;, T., Diamond;, I., Walker;, A. S., & Team, C.-I. 365

366 S. (2021). Impact of Delta on viral burden and vaccine effectiveness against new 367 SARS-CoV-2 infections in the UK *Nuffield Department of Medicine*. 368 Qureshi, A. I., Baskett, W. I., Huang, W., Lobanova, I., Nagvi, S. H., & Shyu, C. R. 369 (2021). Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory 370 Testing. Clin Infect Dis. https://doi.org/10.1093/cid/ciab345 Rennert, L., & McMahan, C. (2021). Risk of SARS-CoV-2 reinfection in a university 371 372 student population. Clin Infect Dis. https://doi.org/10.1093/cid/ciab454 373 Rouse, B. T., & Sehrawat, S. (2010). Immunity and immunopathology to viruses: what 374 decides the outcome? Nat Rev Immunol, 10(7), 514-526. 375 https://doi.org/10.1038/nri2802 376 Sheehan, M. M., Reddy, A. J., & Rothberg, M. B. (2021). Reinfection Rates among 377 Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort 378 Study. Clin Infect Dis. https://doi.org/10.1093/cid/ciab234 379 Shrestha, N. K., Burke, P. C., Nowacki, A. S., Terpeluk, P., & Gordon, S. M. (2021). 380 Necessity of COVID-19 vaccination in previously infected individuals. *medRxiv*. 381 Stephens, D. S., & McElrath, M. J. (2020). COVID-19 and the Path to Immunity. JAMA, 324(13), 1279-1281. https://doi.org/10.1001/jama.2020.16656 382 383 Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., 384 Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., Kuntz, J. L., 385 Dunnigan, K., Odean, M. J., Hegmann, K. T., Stefanski, E., Edwards, L. J., 386 Schaefer-Solle, N., Grant, L., Ellingson, K., Groom, H. C., Zunie, T., Thiese, M. 387 S., Ivacic, L., Wesley, M. G., Lamberte, J. M., Sun, X., Smith, M. E., Phillips, A. 388 L., Groover, K. D., Yoo, Y. M., Gerald, J., Brown, R. T., Herring, M. K., Joseph,

389 G., Beitel, S., Morrill, T. C., Mak, J., Rivers, P., Harris, K. M., Hunt, D. R., Arvay, 390 M. L., Kutty, P., Fry, A. M., & Gaglani, M. (2021). Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing 391 392 SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and 393 Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-394 March 2021. MMWR Morb Mortal Wkly Rep., 70(13), 495-500. 395 https://doi.org/10.15585/mmwr.mm7013e3 396 Vitale, J., Mumoli, N., Clerici, P., De Paschale, M., Evangelista, I., Cei, M., & Mazzone, 397 A. (2021). Assessment of SARS-CoV-2 Reinfection 1 Year After Primary 398 Infection in a Population in Lombardy, Italy. *JAMA Intern Med.* 399 https://doi.org/10.1001/jamainternmed.2021.2959 400

Table. Studies through Aug 8, 2021 that show prior COVID-19 infection reduces risk for re-infection

402

403

Setting	Percent reduction in re-infection	Sample size	Follow up (months)	Reference	
Israel	94.8%	238,702	9.92 million person-months	Goldberg, MedRxiv, April 20, 2021	(Goldberg et al., 2021)
England	84.0%	25,661	Median 9.2 (IQR: 7.3-9.7)	Hall, Lancet, Apr 9, 2021	(Hall et al., 2021)
Denmark	80.5%	525,339	Maximum 10.3	Hansen, Lancet, Mar 27, 2021	(Hansen et al., 2021)
USA	100.0%	5,052	12625.2 person-months	Kojima, MedRxiv, July 8, 2021	(Kojima et al., 2021)
US Marines	82.0%	3,076	All 1.9	Letizia, Lancet Resp Med, Apr 15, 2021	(Letizia et al., 2021)
Austria	91.0%	8,900,480	Maximum 9.4	Pilz, Euro J of Clin Invest, Feb 13, 2021	(Pilz et al., 2021)
USA	84.0%	16,101	All 8.4	Rennert, Clin Inf Dis, May 16, 2021	(Rennert & McMahan, 2021)
USA	81.8%	150,325	Follow up to 9.8	Sheehan, Clin Infect Dis, Mar 15, 2021	(Sheehan et al., 2021)
USA	100.0%	52,238	Median 5.1 (IQR: 2.7-6.4)	Shrestha, MedRxiv, June 1, 2021	(Shrestha et al., 2021)
Italy	94.0%	13,496	Mean 9.3 (SD 1.4)	Vitale, JAMA IM, May 28, 2021	(Vitale et al., 2021)
Weighted average	90.4% +/- 7.65%	9,930,470			

Figure. PRISMA flow diagram for systematic reviews

404

